Sector News

Takeda confirms it's scoping out Shire for a GI-focused buyout bid of up to $52B

March 29, 2018
Life sciences

Shire has long been a popular buyout target, and it’s the latest to catch Takeda’s eye.

Wednesday, the Japanese drugmaker confirmed that it was considering approaching Shire about a potential offer but hadn’t yet gotten in touch with the company’s board.

The reasoning behind its interest? A Shire buy would help Takeda bulk up in oncology, GI and neuroscience, it figures, and it would “accelerate Takeda’s vision to be a leader in specialized medicines that are transformative to patients through the addition of Shire’s leading global rare disease franchise,” too.

The way Bernstein’s Ronny Gal and Wimal Kapadia see it, “shareholders will be interested” as well, despite the analysts’ opinion that “the strategic logic is not apparent.”

“Most Shire shareholders will sell for a 20%-25% premium, given the unclear horizon for stock recovery,” they wrote of Shire’s shares, which have been battered for months. Around noon Wednesday, they had skyrocketed by nearly 15% to about $148, pushing the company’s market cap past $44 billion.

Still, outside of “modest overlap” in GI, they don’t see much in the way of cost-cutting opportunities. And according to their calculations, if Takeda can pull off a deal, it’ll have to cough up more than its market cap and fork over 40% ownership to Shire’s shareholders.

It’s not the first time Takeda has attempted to pin down one of its fellow GI drugmakers. Back in 2016, it reportedly teamed up with TPG on a takeout offer for Valeant that the troubled company turned down, and after that, it pursued a buy of Valeant’s GI unit, Salix, before $10 billion talks broke down.

On the other side of the coin, it’s far from the first time a company has thought about nabbing Shire. Most notably, the Irish company agreed to be picked up by AbbVie back in the days of tax inversion before new, stricter U.S. Treasury rules convinced AbbVie to nix the pact in October 2014.

Next up: Per U.K. rules, Takeda will have to produce an offer or walk away by April 25. And in the meantime, other suitors could come out of the woodwork.

“We expect most large pharma companies have a takeout model of Shire,” the Bernstein analyst wrote, adding that “Takeda’s announcement will force them to make a decision whether they want to step up.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach